<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04852978</url>
  </required_header>
  <id_info>
    <org_study_id>R10933-10987-COV-2118</org_study_id>
    <nct_id>NCT04852978</nct_id>
  </id_info>
  <brief_title>COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers</brief_title>
  <official_title>A Phase 2 Randomized, Open-Label, Parallel Group Study to Assess the Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objectives of the study are:&#xD;
&#xD;
        -  To evaluate the extent of effect, if any, of REGN10933+REGN10987 administration on&#xD;
           vaccine-induced neutralizing antibody responses to SARS-CoV-2 by Moderna mRNA-1273&#xD;
&#xD;
        -  To evaluate the time interval required between REGN10933+REGN10987 administration and&#xD;
           Moderna mRNA-1273 vaccination, to ensure no meaningful impact on vaccine-induced&#xD;
           neutralizing antibody responses to SARS-CoV-2&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To quantify the alteration of antigen specificity of vaccine-induced SARS-CoV-2 antibody&#xD;
           responses when administered with different dose regimens of REGN10933+REGN10987&#xD;
&#xD;
        -  To evaluate the safety and tolerability of REGN10933+REGN10987 and Moderna mRNA-1273&#xD;
           vaccine when administered in close succession&#xD;
&#xD;
        -  To assess the concentrations of REGN10933 and REGN10987 in serum over time in&#xD;
           participants who receive REGN10933+REGN10987 and Moderna mRNA-1273 vaccine&#xD;
&#xD;
        -  To evaluate the immunogenicity of REGN10933 and REGN10987 over time&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 29, 2021</start_date>
  <completion_date type="Anticipated">November 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>50% inhibitory dilution (ID50) titers of vaccine-induced neutralizing antibodies to the SARS-CoV-2 S protein</measure>
    <time_frame>56 days after first dose of vaccine</time_frame>
    <description>High dose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>50% inhibitory dilution (ID50) titers of vaccine-induced neutralizing antibodies to the SARS-CoV-2 S protein</measure>
    <time_frame>56 days after first dose of vaccine</time_frame>
    <description>Submaximal dose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute values in concentrations of vaccine-induced antibodies to SARS-CoV-2 antigens over time</measure>
    <time_frame>Up to 401 Days</time_frame>
    <description>Anti-S protein&#xD;
Anti-RBD&#xD;
Other S protein subdomains (including S1, S2, and NTD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in concentrations of vaccine-induced antibodies to SARS-CoV-2 antigens over time</measure>
    <time_frame>Up to 401 Days</time_frame>
    <description>Anti-S protein&#xD;
Anti-RBD&#xD;
Other S protein subdomains (including S1, S2, and NTD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from baseline in concentrations of vaccine-induced antibodies to SARS-CoV-2 antigens over time</measure>
    <time_frame>Up to 401 Days</time_frame>
    <description>Anti-S protein&#xD;
Anti-RBD&#xD;
Other S protein subdomains (including S1, S2, and NTD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>50% inhibitory dilution (ID50) titers of vaccine-induced neutralizing antibodies to SARS-CoV-2 S protein assessed over time after the first dose of Moderna mRNA-1273 vaccine</measure>
    <time_frame>Up to 401 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with treatment-emergent adverse events (TEAEs) throughout the study</measure>
    <time_frame>Up to 401 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with treatment-emergent serious adverse events (SAEs) throughout the study</measure>
    <time_frame>Up to 401 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with infusion-related reactions (grade ≥2) to REGN10933+REGN10987</measure>
    <time_frame>Through Day 4 post-infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with injection site reactions (grade ≥3) to REGN10933+REGN10987 or each dose of Moderna mRNA-1273 vaccine</measure>
    <time_frame>Through Day 4 post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with hypersensitivity reactions (grade ≥2) to REGN10933+REGN10987 or each dose of Moderna mRNA-1273 vaccine</measure>
    <time_frame>Through Day 29 post-infusion or post-injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of REGN10933 in serum over time</measure>
    <time_frame>Up to Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentrations of REGN10987 in serum over time</measure>
    <time_frame>Up to Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity, as measured by anti-drug antibodies (ADA) to REGN10933</measure>
    <time_frame>Up to Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity, as measured by ADA to REGN10987</measure>
    <time_frame>Up to Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity, as measured by neutralizing antibodies (NAb) to REGN10933</measure>
    <time_frame>Up to Day 183</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity, as measured by NAb to REGN10987</measure>
    <time_frame>Up to Day 183</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">286</enrollment>
  <condition>Healthy</condition>
  <condition>Chronic Stable Illness</condition>
  <arm_group>
    <arm_group_label>Wave 1 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 1 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 1 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 1 Vaccine only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 2 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 2 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 2 Vaccine only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 3 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 3 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 3 Vaccine only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 4 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Wave 4 Vaccine only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>casirivimab+imdevimab</intervention_name>
    <description>Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration</description>
    <arm_group_label>Wave 1 Dose 1</arm_group_label>
    <arm_group_label>Wave 1 Dose 2</arm_group_label>
    <arm_group_label>Wave 1 Dose 3</arm_group_label>
    <arm_group_label>Wave 2 Dose 1</arm_group_label>
    <arm_group_label>Wave 2 Dose 2</arm_group_label>
    <arm_group_label>Wave 3 Dose 1</arm_group_label>
    <arm_group_label>Wave 3 Dose 2</arm_group_label>
    <arm_group_label>Wave 4 Dose 1</arm_group_label>
    <other_name>REGN10933</other_name>
    <other_name>REGN10987</other_name>
    <other_name>REGN-COV2</other_name>
    <other_name>REGEN-COV™</other_name>
    <other_name>Ronapreve™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Moderna mRNA-1273 vaccine</intervention_name>
    <description>Single intramuscular (IM) injection</description>
    <arm_group_label>Wave 1 Dose 1</arm_group_label>
    <arm_group_label>Wave 1 Dose 2</arm_group_label>
    <arm_group_label>Wave 1 Dose 3</arm_group_label>
    <arm_group_label>Wave 1 Vaccine only</arm_group_label>
    <arm_group_label>Wave 2 Dose 1</arm_group_label>
    <arm_group_label>Wave 2 Dose 2</arm_group_label>
    <arm_group_label>Wave 2 Vaccine only</arm_group_label>
    <arm_group_label>Wave 3 Dose 1</arm_group_label>
    <arm_group_label>Wave 3 Dose 2</arm_group_label>
    <arm_group_label>Wave 3 Vaccine only</arm_group_label>
    <arm_group_label>Wave 4 Dose 1</arm_group_label>
    <arm_group_label>Wave 4 Vaccine only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Healthy or has chronic medical condition(s) that are stable and well-controlled in the&#xD;
             opinion of the investigator and that are not likely to require significant medical&#xD;
             intervention through the end of study&#xD;
&#xD;
          2. Willing and able to comply with study visits and study-related procedures, including&#xD;
             compliance with site precautionary requirements related to SARS-CoV-2 infection and&#xD;
             transmission&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Positive RT-PCR test result for SARS-CoV-2 infection at screening or baseline&#xD;
&#xD;
          2. Positive serology test result for anti-SARS-CoV-2 antibodies at screening or baseline&#xD;
&#xD;
          3. COVID-19 diagnosis, positive SARS-CoV-2 infection, or positive SARS-CoV-2 serology at&#xD;
             any time prior to screening&#xD;
&#xD;
          4. Previously received an investigational, authorized, or approved coronavirus vaccine&#xD;
             (eg, SARS-CoV-2 vaccine, MERS-CoV vaccine)&#xD;
&#xD;
          5. Currently enrolled in, or has plans to enroll in, any interventional study to prevent&#xD;
             or treat COVID-19&#xD;
&#xD;
          6. Received investigational or approved passive antibodies for SARS-CoV-2 infection&#xD;
             prophylaxis ad defined in the protocol&#xD;
&#xD;
          7. Received intravenous immunoglobulin (IVIG) or blood products in the last 3 months&#xD;
&#xD;
          8. Any physical examination findings and/or history of any illness that, in the opinion&#xD;
             of the study investigator, might confound the results of the study or pose an&#xD;
             additional risk to the subject by study participation&#xD;
&#xD;
          9. History of clinically significant cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as&#xD;
             assessed by the investigator, that may confound the results of the study or pose an&#xD;
             additional risk to the subject by study participation&#xD;
&#xD;
         10. Medically attended acute illness or hospitalization (ie, &gt;24 hours) for any reason&#xD;
             within 30 days prior to screening&#xD;
&#xD;
         11. Clinical history of myocarditis and/or pericarditis&#xD;
&#xD;
        Note: Other protocol-defined Inclusion/ Exclusion Criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trials Administrator</last_name>
    <phone>844-734-6643</phone>
    <email>clinicaltrials@regeneron.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regeneron Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

